On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...
AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...
Begin your TipRanks Premium journey today. AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye ...
Stocktwits on MSN7d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
Shares of AbbVie Inc. ABBV shed 2.74% to $164.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.32% to 5,870.62 and Dow ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback